Igor Łoniewski

Nonsteroidal anti-inflammatory drugs, proton pump inhibitors, and gastrointestinal injury: contrasting interactions in the stomach and small intestine.

Nonsteroidal anti-inflammatory drugs (NSAIDs) and proton pump inhibitors (PPIs) are among the most frequently prescribed groups of drugs worldwide. The use of NSAIDs is associated with a high number of significant adverse effects. Recently, the safety of PPIs has also been challenged. Capsule endoscopy studies reveal that even low-dose NSAIDs are responsible for gut mucosal injury and numerous clinical adverse effects, for example, bleeding and anemia, that might be difficult to diagnose. The frequent use of PPIs can exacerbate NSAID-induced small intestinal injury by altering intestinal microbiota. Thus, the use of PPI is considered to be an independent risk factor associated with NSAID-associated enteropathy. In this review, we discuss this important clinical problem and review relevant aspects of epidemiology, pathophysiology, and management. We also present the hypothesis that even minor and subclinical injury to the intestinal mucosa can result in significant, though delayed, metabolic consequences, which may seriously affect the health of an individual. PubMed was searched using the following key words (each key word alone and in combination): gut microbiota, microbiome, non-steroidal anti inflammatory drugs, proton pump inhibitors, enteropathy, probiotic, antibiotic, mucosal injury, enteroscopy, and capsule endoscopy. Google engine search was also carried out to identify additional relevant articles. Both original and review articles published in English were reviewed.

Emerging concepts in non-invasive monitoring of Crohn’s disease:

Inflammatory bowel disease (IBD) is an umbrella term for Crohn’s disease (CD) and ulcerative colitis (UC). In light of evolving epidemiology of CD, its clinical management is still complex and remains a challenge for contemporary physicians. With the advent of new diagnostic and treatment paradigms, there is a growing need for new biomarkers to guide decision-making, differential diagnosis, disease activity monitoring, as well as prognosis. However, both clinical and endoscopic scoring systems, widely utilized for disease monitoring and prognosis, have drawbacks and limitations. In recent years, biochemical peptides have become available for IBD monitoring and more frequently used as surrogate markers of gut inflammation. Emerging concepts that revolve around molecular, stem cell, epigenetic, microbial or metabolomic pathways associated with vascular and epithelial gut barrier could lead to development of new CD biomarkers. Measurement of cell-derived microvesicles (MVs) in the blood of IBD patients is another emerging concept helpful in future disease management. In this review, we discuss novel concepts of non-invasive biomarkers, which may become useful in monitoring of CD activity and prognosis. We discuss metabolomics as a new powerful tool for clinicians to guide differential IBD diagnosis. In the coming years, new developments of prognostic tools are expected, aiming for breakthroughs in the management of patients with CD.

Test and Treat H. Pylori Eradication in Dyspepsia—“A Bridge too Far” in the Concensus?

REFERENCES 1. Kanwal F , Tansel A , Kramer JR et al. Trends in 30-day and 1-year mortality among patients hospitalized with cirrhosis from 2004 to 2013 . Am J Gastroenterol 2017 ; 112 : 1287 – 97 . 2. Lopez Bernal J , Cummins S , Gasparrini A . Interrupted time series regression for the evaluation of public health interventions: a tutorial . Int J Epidemiol 2017 ; 46 : 348 – 55 . 3. Centers for Medicare & Medicaid Services . FY 2016 IPPS fi nal rules: Hospital Readmission Reduction Program supplemental data fi les https://www.cms.gov/Medicare/MedicareFee-for-Service-Payment/AcuteInpatientPPS/ Readmissions-Reduction-Program.html . Accessed on 27 July 2017 . 4. Dharmarajan K , Wang Y , Lin Z et al. Association of changing hospital readmission rates with mortality rates aft er hospital discharge . JAMA 2017 ; 318 : 270 – 8 . 5. Shen J , Ko E , Kim P et al. National temporal trends of intensive medical procedures and palliative care among hospitalized patients with chronic obstructive pulmonary disease in the U.S. Am J Hosp Palliat Med. [in press] .